サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1566764

脊椎生物製剤市場：製品別、エンドユーザー別：世界の機会分析と産業予測、2024～2033年

Spine Biologics Market By Product (Spinal Allografts, Bone Graft Substitutes, Cell-Based Matrix) , By End User (Hospitals, Outpatient Facilities) : Global Opportunity Analysis and Industry Forecast, 2024-2033

出版日
ページ情報
英文 280 Pages
納期
2～3営業日
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
脊椎生物製剤市場：製品別、エンドユーザー別：世界の機会分析と産業予測、2024～2033年
出版日: 2024年07月10日
発行: Allied Market Research
ページ情報: 英文 280 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

脊椎生物製剤市場

脊椎生物製剤市場は、2023年に30億5,000万米ドルと評価され、2024～2035年のCAGRは5.29%を示し、2035年には55億5,000万米ドルに達すると推定されます。

脊椎生物製剤は、脊椎の癒合を促進し、治癒を促進し、いくつかの脊椎疾患を治療する材料で構成されています。この材料には、成長因子、幹細胞、骨移植片が含まれ、身体の自然治癒プロセスを助ける。骨移植片は、新しい骨の成長に必要な足場です。骨移植片には、患者自身の体に由来する自家移植片と、ドナーに由来する同種移植片があります。幹細胞は、完全な機能性を持つ新しい細胞を生成する能力を持つ特別な細胞であり、骨形態形成タンパク質（BMP）などの成長因子は、再生と骨修復のために細胞を刺激する役割を果たします。脊椎生物製剤の使用は、2つ以上の椎骨を接合する脊椎固定術において広く行われています。

脊椎疾患の有病率の増加、特に急増する高齢者人口における増加は、脊椎生物製剤市場の主要な促進要因です。さらに、低侵襲手術への傾斜が高まる中、脊椎手術中の侵襲を最小限に抑え、治癒を促進する脊椎生物製剤の需要が急増しています。最近の動向では、骨移植代替物の開発に積層造形法を使用することが市場の新たな傾向となっています。これらの代用品は、生体による拒絶反応の可能性がある骨移植片と比較して、同等の有効性と改善された安全性を記載しています。

しかし、脊椎生物製剤の開発は複雑な手順であり、費用もかさむため、市場の発展を抑制しています。さらに、脊椎手術に十分な保険が適用されない非効果的な償還政策が、高額な治療を受けることを躊躇させ、市場の成長を制限しています。それとは逆に、脊椎損傷の件数は常に増加しており、脊椎生物製剤の需要を将来的に促進すると予想されています。米国国立医療図書館が最近発表した論文によると、米国では毎年、新たに発生する脊髄損傷の38%が自動車事故によるもので、転倒は脊髄損傷の2番目に多い理由で、全体の30%を占めています。

セグメント別レビュー

脊椎生物製剤市場は、製品、エンドユーザー、地域に区分されます。製品別では、脊椎同種移植片、骨移植代替物、細胞ベースマトリックスに分けられます。エンドユーザー別では、病院と外来施設に二分されます。地域別では、北米、欧州、アジア太平洋、ラテンアメリカ・中東・アフリカで分析されています。

主要調査結果

製品別では、脊椎移植片セグメントが2023年の市場を独占しました。

エンドユーザー別では、病院セグメントが2023年の市場で高いシェアを獲得しました。

地域別では、北米が2035年までに最も高い収益を上げると予測されています。

本レポートのカスタマイズが可能です。

  • 規制ガイドライン
  • クライアントの関心に応じた企業プロファイルの追加
  • 国別または地域別の追加分析-市場規模と予測
  • 企業プロファイルの拡大リスト
  • 過去の市場データ
  • 主要参入企業の詳細（所在地、連絡先、サプライヤー/ベンダーネットワークなどを含む、エクセル形式）

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場情勢

  • 市場の定義と範囲
  • 主要調査結果
    • 主要投資機会
    • 主要成功戦略
  • ポーターのファイブフォース分析
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会

第4章 脊椎生物製剤市場：製品別

  • 市場概要
  • 脊椎移植片
  • 骨移植代替物
  • 細胞ベースマトリックス

第5章 脊椎生物製剤市場：エンドユーザー別

  • 市場概要
  • 病院
  • 外来患者施設

第6章 脊椎生物製剤市場：地域別

  • 市場概要
  • 北米
    • 主要市場動向と機会
    • 米国の脊椎生物製剤市場
    • カナダの脊椎生物製剤市場
    • メキシコの脊椎生物製剤市場
  • 欧州
    • 主要市場動向と機会
    • ドイツの脊椎生物製剤市場
    • フランスの脊椎生物製剤市場
    • 英国の脊椎生物製剤市場
    • イタリアの脊椎生物製剤市場
    • スペインの脊椎生物製剤市場
    • その他の欧州の脊椎生物製剤市場
  • アジア太平洋
    • 主要市場動向と機会
    • 日本の脊椎生物製剤市場
    • 中国の脊椎生物製剤市場
    • オーストラリアの脊椎生物製剤市場
    • インドの脊椎生物製剤市場
    • 韓国の脊椎生物製剤市場
    • その他のアジア太平洋の脊椎生物製剤市場
  • ラテンアメリカ・中東・アフリカ
    • 主要市場動向と機会
    • ブラジルの脊椎生物製剤市場
    • サウジアラビアの脊椎生物製剤市場
    • 南アフリカの脊椎生物製剤市場
    • その他のラテンアメリカ・中東・アフリカの脊椎生物製剤市場

第7章 競合情勢

  • イントロダクション
  • 主要成功戦略
  • 主要10企業の製品マッピング
  • 競合ダッシュボード
  • 競合ヒートマップ
  • 主要企業のポジショニング（2023年）

第8章 企業プロファイル

  • Stryker Corporation
  • NuVasive, Inc.
  • Orthofix
  • Johnson And Johnson
  • Exactech, Inc
  • Zimmer Biomet Holding, Inc.
  • Arthrex, Inc.
  • Medtronic Plc
  • Organogenesis Inc
  • Kuros Biosciences
目次
Product Code: A01625

Spine Biologics Market

The spine biologics market was valued at $3.05 billion in 2023 and is estimated to reach $5.55 billion by 2035, exhibiting a CAGR of 5.29% from 2024 to 2035.

Spine biologics comprises of materials that enhance spinal fusion, promote healing, and treat several spinal disorders. The materials involve growth factors, stem cells, and bone grafts, which help in the natural healing processes of the body. Bone grafts are the scaffolds required for new bone growth. They include autografts, which belong to patient's own body, and allografts, which are derived from a donor. Stem cells are a special form of cells that have the ability to generate new cells with complete functionalities and growth factors, such as bone morphogenetic proteins (BMPs), play role in stimulating the cells for regeneration and bone repair. The usage of spine biologics is widespread in spinal fusion surgeries, which involve the joining of two or more vertebrae.

Increase in the prevalence of spinal disorders, particularly in the exponentially growing geriatric population, is a key driver of the spine biologics market. In addition, with rising inclination toward minimally invasive procedures, the demand for spine biologics is surging as they facilitate minimal invasion during spinal surgeries and promote healing. In recent times, the use of additive manufacturing for the development of bone graft substitute is an emerging trend in the market. These substitutes offer equivalent efficacy and improved safety when compared to bone grafts, which hold the potential for rejection by the body.

However, the development of spine biologics is a complex procedure with high expenses, hence restraining the development of the market. Furthermore, the ineffective reimbursement policies that do not offer adequate cover for spinal surgeries deter individuals from undergoing expensive treatments, hence limiting the market growth. On the contrary, the consistently rising numbers of spinal injuries are anticipated to propel the demand for spine biologics in the future. The National Library of Medicine recently published an article which reported that every year 38% of new spinal cord injuries occur due to motor vehicular crashes in the U.S. falling is the second most prevalent reason for spinal injuries, accounting for 30% of the total count.

Segment Review

The spine biologics market is segmented into product, end user, and region. By product, the market is divided into spinal allografts, bone graft substitutes, and cell-based matrix. As per end user, it is bifurcated into hospitals and outpatient facilities. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

By product, the spinal allografts segment dominated the market in 2023.

As per end user, the hospital segment acquired a high stake in the market in 2023.

Region wise, North America is projected to be the highest revenue generator by 2035.

Competition Analysis

The major players operating in the spine biologics market are Stryker, NuVasive, Inc., Orthofix, Johnson & Johnson, Exactech, Inc., Zimmer Biomet. Arthrex, Inc., Medtronic Plc, Organogenesis Inc., and Kuros Biosciences. These players have adopted various key developmental strategies such as business expansion, new product launches, and partnerships to strengthen their foothold in the market.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Product

  • Spinal Allografts
  • Bone Graft Substitutes
  • Cell-Based Matrix

By End User

  • Hospitals
  • Outpatient Facilities

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • Stryker Corporation
    • NuVasive, Inc.
    • orthofix
    • Johnson & Johnson
    • Exactech, Inc
    • Zimmer Biomet Holding, Inc.
    • Arthrex, Inc.
    • Medtronic plc
    • Organogenesis Inc
    • Kuros Biosciences

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report Description
  • 1.2. Key Market Segments
  • 1.3. Key Benefits
  • 1.4. Research Methodology
    • 1.4.1. Primary Research
    • 1.4.2. Secondary Research
    • 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

  • 3.1. Market Definition and Scope
  • 3.2. Key Findings
    • 3.2.1. Top Investment Pockets
    • 3.2.2. Top Winning Strategies
  • 3.3. Porter's Five Forces Analysis
    • 3.3.1. Bargaining Power of Suppliers
    • 3.3.2. Threat of New Entrants
    • 3.3.3. Threat of Substitutes
    • 3.3.4. Competitive Rivalry
    • 3.3.5. Bargaining Power among Buyers
  • 3.4. Market Dynamics
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities

CHAPTER 4: SPINE BIOLOGICS MARKET, BY PRODUCT

  • 4.1. Market Overview
    • 4.1.1 Market Size and Forecast, By Product
  • 4.2. Spinal Allografts
    • 4.2.1. Key Market Trends, Growth Factors and Opportunities
    • 4.2.2. Market Size and Forecast, By Region
    • 4.2.3. Market Share Analysis, By Country
  • 4.3. Bone Graft Substitutes
    • 4.3.1. Key Market Trends, Growth Factors and Opportunities
    • 4.3.2. Market Size and Forecast, By Region
    • 4.3.3. Market Share Analysis, By Country
  • 4.4. Cell-Based Matrix
    • 4.4.1. Key Market Trends, Growth Factors and Opportunities
    • 4.4.2. Market Size and Forecast, By Region
    • 4.4.3. Market Share Analysis, By Country

CHAPTER 5: SPINE BIOLOGICS MARKET, BY END USER

  • 5.1. Market Overview
    • 5.1.1 Market Size and Forecast, By End User
  • 5.2. Hospitals
    • 5.2.1. Key Market Trends, Growth Factors and Opportunities
    • 5.2.2. Market Size and Forecast, By Region
    • 5.2.3. Market Share Analysis, By Country
  • 5.3. Outpatient Facilities
    • 5.3.1. Key Market Trends, Growth Factors and Opportunities
    • 5.3.2. Market Size and Forecast, By Region
    • 5.3.3. Market Share Analysis, By Country

CHAPTER 6: SPINE BIOLOGICS MARKET, BY REGION

  • 6.1. Market Overview
    • 6.1.1 Market Size and Forecast, By Region
  • 6.2. North America
    • 6.2.1. Key Market Trends and Opportunities
    • 6.2.2. Market Size and Forecast, By Product
    • 6.2.3. Market Size and Forecast, By End User
    • 6.2.4. Market Size and Forecast, By Country
    • 6.2.5. U.S. Spine Biologics Market
      • 6.2.5.1. Market Size and Forecast, By Product
      • 6.2.5.2. Market Size and Forecast, By End User
    • 6.2.6. Canada Spine Biologics Market
      • 6.2.6.1. Market Size and Forecast, By Product
      • 6.2.6.2. Market Size and Forecast, By End User
    • 6.2.7. Mexico Spine Biologics Market
      • 6.2.7.1. Market Size and Forecast, By Product
      • 6.2.7.2. Market Size and Forecast, By End User
  • 6.3. Europe
    • 6.3.1. Key Market Trends and Opportunities
    • 6.3.2. Market Size and Forecast, By Product
    • 6.3.3. Market Size and Forecast, By End User
    • 6.3.4. Market Size and Forecast, By Country
    • 6.3.5. Germany Spine Biologics Market
      • 6.3.5.1. Market Size and Forecast, By Product
      • 6.3.5.2. Market Size and Forecast, By End User
    • 6.3.6. France Spine Biologics Market
      • 6.3.6.1. Market Size and Forecast, By Product
      • 6.3.6.2. Market Size and Forecast, By End User
    • 6.3.7. UK Spine Biologics Market
      • 6.3.7.1. Market Size and Forecast, By Product
      • 6.3.7.2. Market Size and Forecast, By End User
    • 6.3.8. Italy Spine Biologics Market
      • 6.3.8.1. Market Size and Forecast, By Product
      • 6.3.8.2. Market Size and Forecast, By End User
    • 6.3.9. Spain Spine Biologics Market
      • 6.3.9.1. Market Size and Forecast, By Product
      • 6.3.9.2. Market Size and Forecast, By End User
    • 6.3.10. Rest of Europe Spine Biologics Market
      • 6.3.10.1. Market Size and Forecast, By Product
      • 6.3.10.2. Market Size and Forecast, By End User
  • 6.4. Asia-Pacific
    • 6.4.1. Key Market Trends and Opportunities
    • 6.4.2. Market Size and Forecast, By Product
    • 6.4.3. Market Size and Forecast, By End User
    • 6.4.4. Market Size and Forecast, By Country
    • 6.4.5. Japan Spine Biologics Market
      • 6.4.5.1. Market Size and Forecast, By Product
      • 6.4.5.2. Market Size and Forecast, By End User
    • 6.4.6. China Spine Biologics Market
      • 6.4.6.1. Market Size and Forecast, By Product
      • 6.4.6.2. Market Size and Forecast, By End User
    • 6.4.7. Australia Spine Biologics Market
      • 6.4.7.1. Market Size and Forecast, By Product
      • 6.4.7.2. Market Size and Forecast, By End User
    • 6.4.8. India Spine Biologics Market
      • 6.4.8.1. Market Size and Forecast, By Product
      • 6.4.8.2. Market Size and Forecast, By End User
    • 6.4.9. South Korea Spine Biologics Market
      • 6.4.9.1. Market Size and Forecast, By Product
      • 6.4.9.2. Market Size and Forecast, By End User
    • 6.4.10. Rest of Asia-Pacific Spine Biologics Market
      • 6.4.10.1. Market Size and Forecast, By Product
      • 6.4.10.2. Market Size and Forecast, By End User
  • 6.5. LAMEA
    • 6.5.1. Key Market Trends and Opportunities
    • 6.5.2. Market Size and Forecast, By Product
    • 6.5.3. Market Size and Forecast, By End User
    • 6.5.4. Market Size and Forecast, By Country
    • 6.5.5. Brazil Spine Biologics Market
      • 6.5.5.1. Market Size and Forecast, By Product
      • 6.5.5.2. Market Size and Forecast, By End User
    • 6.5.6. Saudi Arabia Spine Biologics Market
      • 6.5.6.1. Market Size and Forecast, By Product
      • 6.5.6.2. Market Size and Forecast, By End User
    • 6.5.7. South Africa Spine Biologics Market
      • 6.5.7.1. Market Size and Forecast, By Product
      • 6.5.7.2. Market Size and Forecast, By End User
    • 6.5.8. Rest of LAMEA Spine Biologics Market
      • 6.5.8.1. Market Size and Forecast, By Product
      • 6.5.8.2. Market Size and Forecast, By End User

CHAPTER 7: COMPETITIVE LANDSCAPE

  • 7.1. Introduction
  • 7.2. Top Winning Strategies
  • 7.3. Product Mapping of Top 10 Player
  • 7.4. Competitive Dashboard
  • 7.5. Competitive Heatmap
  • 7.6. Top Player Positioning, 2023

CHAPTER 8: COMPANY PROFILES

  • 8.1. Stryker Corporation
    • 8.1.1. Company Overview
    • 8.1.2. Key Executives
    • 8.1.3. Company Snapshot
    • 8.1.4. Operating Business Segments
    • 8.1.5. Product Portfolio
    • 8.1.6. Business Performance
    • 8.1.7. Key Strategic Moves and Developments
  • 8.2. NuVasive, Inc.
    • 8.2.1. Company Overview
    • 8.2.2. Key Executives
    • 8.2.3. Company Snapshot
    • 8.2.4. Operating Business Segments
    • 8.2.5. Product Portfolio
    • 8.2.6. Business Performance
    • 8.2.7. Key Strategic Moves and Developments
  • 8.3. Orthofix
    • 8.3.1. Company Overview
    • 8.3.2. Key Executives
    • 8.3.3. Company Snapshot
    • 8.3.4. Operating Business Segments
    • 8.3.5. Product Portfolio
    • 8.3.6. Business Performance
    • 8.3.7. Key Strategic Moves and Developments
  • 8.4. Johnson And Johnson
    • 8.4.1. Company Overview
    • 8.4.2. Key Executives
    • 8.4.3. Company Snapshot
    • 8.4.4. Operating Business Segments
    • 8.4.5. Product Portfolio
    • 8.4.6. Business Performance
    • 8.4.7. Key Strategic Moves and Developments
  • 8.5. Exactech, Inc
    • 8.5.1. Company Overview
    • 8.5.2. Key Executives
    • 8.5.3. Company Snapshot
    • 8.5.4. Operating Business Segments
    • 8.5.5. Product Portfolio
    • 8.5.6. Business Performance
    • 8.5.7. Key Strategic Moves and Developments
  • 8.6. Zimmer Biomet Holding, Inc.
    • 8.6.1. Company Overview
    • 8.6.2. Key Executives
    • 8.6.3. Company Snapshot
    • 8.6.4. Operating Business Segments
    • 8.6.5. Product Portfolio
    • 8.6.6. Business Performance
    • 8.6.7. Key Strategic Moves and Developments
  • 8.7. Arthrex, Inc.
    • 8.7.1. Company Overview
    • 8.7.2. Key Executives
    • 8.7.3. Company Snapshot
    • 8.7.4. Operating Business Segments
    • 8.7.5. Product Portfolio
    • 8.7.6. Business Performance
    • 8.7.7. Key Strategic Moves and Developments
  • 8.8. Medtronic Plc
    • 8.8.1. Company Overview
    • 8.8.2. Key Executives
    • 8.8.3. Company Snapshot
    • 8.8.4. Operating Business Segments
    • 8.8.5. Product Portfolio
    • 8.8.6. Business Performance
    • 8.8.7. Key Strategic Moves and Developments
  • 8.9. Organogenesis Inc
    • 8.9.1. Company Overview
    • 8.9.2. Key Executives
    • 8.9.3. Company Snapshot
    • 8.9.4. Operating Business Segments
    • 8.9.5. Product Portfolio
    • 8.9.6. Business Performance
    • 8.9.7. Key Strategic Moves and Developments
  • 8.10. Kuros Biosciences
    • 8.10.1. Company Overview
    • 8.10.2. Key Executives
    • 8.10.3. Company Snapshot
    • 8.10.4. Operating Business Segments
    • 8.10.5. Product Portfolio
    • 8.10.6. Business Performance
    • 8.10.7. Key Strategic Moves and Developments